Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21097989 | 0.88 | KDM4C (0.31) | KDM4CNPC1RAB9ALPAR1 | |
| SCHEMBL21058053 | 0.87 | LPAR1 (0.40) | KDM4CNPC1RAB9ALPAR1MEN1 | |
| SCHEMBL29180468 | 0.81 | GRIN1 (0.32) | KDM4CNPC1RAB9A | |
| SCHEMBL30740321 | 0.81 | GRIN1 (0.32) | KDM4CNPC1RAB9A | |
| SCHEMBL29180491 | 0.79 | PDE8B (0.33) | KDM4CNPC1RAB9A | |
| SCHEMBL30740284 | 0.79 | PDE8B (0.33) | KDM4CNPC1RAB9A | |
| SCHEMBL21058017 | 0.77 | GABRA5 (0.40) | KDM4CNPC1RAB9ALPAR1MEN1 | |
| SCHEMBL25422781 | 0.76 | SLCO1B1 (0.39) | KDM4CNPC1RAB9AMEN1KMT2A | |
| SCHEMBL19715646 | 0.76 | PDE8B (0.32) | — | |
| SCHEMBL22252469 | 0.75 | P2RX3 (0.38) | NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112189010-B | Triazole N-linked carbamoyl cyclohexyl acid as LPA antagonists | 百时美施贵宝公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-02-27 | — | — | US | disclosed |
| US-12195444-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-14 | — | — | US | disclosed |
| CN-112055711-B | Cyclohexylic acid triazolazine as LPA antagonist | 百时美施贵宝公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-112521368-B | Triazole N-linked carbamoyl cyclohexyl acid as LPA antagonists | 百时美施贵宝公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3728223-B1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11267800-B2 | Cyclohexyl acid triazole azines as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3710438-B1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-29 | — | — | US | disclosed |
| US-11008300-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| CN-112521368-A | Triazole N-linked carbamoylcyclohexanoic acids as LPA antagonists | 百时美施贵宝公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-112189010-A | Triazole N-linked carbamoylcyclohexanoic acids as LPA antagonists | 百时美施贵宝公司 | 2021-01-05 | — | — | CN | disclosed |
| EP-3728223-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200148665-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-14 | — | — | US | disclosed |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267800-B2 | Cyclohexyl acid triazole azines as LPA antagonists | LPAR3, LPAR1, LPAR2 | KDM4C 3654/4885NPC1 396/4885RAB9A 2179/4885 |
| US-20210230143-A1 | CYCLOHEXYL ACID TRIAZOLE AZINES AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | KDM4C 3654/4885NPC1 396/4885RAB9A 2179/4885 |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | KDM4C 3140/4885NPC1 250/4885RAB9A 1907/4885 |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | KDM4C 3140/4885NPC1 250/4885RAB9A 1907/4885 |
| US-20200148665-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | KDM4C 3140/4885NPC1 250/4885RAB9A 1907/4885 |
| US-20250066341-A1 | CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | KDM4C 3100/4885NPC1 317/4885RAB9A 2476/4885 |
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | KDM4C 3140/4885NPC1 250/4885RAB9A 1907/4885 |
| US-20230339884-A1 | Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists | LPAR3, LPAR1, LPAR2 | KDM4C 3140/4885NPC1 250/4885RAB9A 1907/4885 |
| US-12195444-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | KDM4C 3140/4885NPC1 250/4885RAB9A 1907/4885 |
| US-11008300-B2 | Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | KDM4C 3140/4885NPC1 250/4885RAB9A 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.